A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed. |
Citations|
| US4172094 | Dec 3, 1976 | Oct 23, 1979 | Merck & Co., Inc. | Polyamine compounds | | US4618619 | Mar 14, 1984 | Oct 21, 1986 | Bayer Aktiengesellschaft | Substituted t-butanol fungicidal agents | | US4644055 | Dec 17, 1984 | Feb 17, 1987 | E. I. Du Pont de Nemours and Company | Method for preparing specific inhibitors of virus-specified proteases | | US4652552 | Sep 10, 1984 | Mar 24, 1987 | E. I. Du Pont de Nemours and Company | Tetrapeptide methyl ketone inhibitors of viral proteases | | US5142056 | May 9, 1990 | Aug 25, 1992 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US5354866 | Sep 14, 1993 | Oct 11, 1994 | Abbott Laboratories | Retroviral protease inhibiting compounds |
Referenced by|
| US5886036 | Mar 20, 1997 | Mar 23, 1999 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US6017928 | Oct 6, 1997 | Jan 25, 2000 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US6037157 | Jun 26, 1996 | Mar 14, 2000 | Abbott Laboratories | Method for improving pharmacokinetics | | US6284767 | Dec 8, 1998 | Sep 4, 2001 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US6472529 | Apr 18, 2001 | Oct 29, 2002 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US6703403 | Sep 20, 2001 | Mar 9, 2004 | Abbott Laboratories | Method for improving pharmacokinetics | | US7148359 | May 4, 2005 | Dec 12, 2006 | Abbott Laboratories | Polymorph of a pharmaceutical | | US7183416 | Jul 29, 2004 | Feb 27, 2007 | Abbott Laboratories | Polymorph of a pharmaceutical | | US7279582 | Oct 25, 2002 | Oct 9, 2007 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US7659405 | Sep 21, 2006 | Feb 9, 2010 | Abbott Laboratories | Polymorph of a pharmaceutical | | US7939553 | Jul 6, 2007 | May 10, 2011 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics | | US7968707 | Feb 27, 2007 | Jun 28, 2011 | Abbott Laboratories | Retroviral protease inhibiting compounds | | US8025899 | Aug 25, 2004 | Sep 27, 2011 | Abbott Laboratories | Solid pharmaceutical dosage form | | US8067449 | Jul 6, 2007 | Nov 29, 2011 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics | | US8088770 | Jul 3, 2008 | Jan 3, 2012 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics | | US8148374 | Feb 22, 2008 | Apr 3, 2012 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics | | US8193367 | Dec 22, 2009 | Jun 5, 2012 | Abbott Laboratories | Polymorph of a pharmaceutical | | USRE42889 | Apr 23, 2007 | Nov 1, 2011 | G.D. Searle LLC | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Claims1. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of another HIV protease inhibiting compound. 2. The method of claim 1 wherein the other HIV inhibiting is selected from the group of Ro 31-8959 SC-52151 KNI-227 and KNI-272. 3. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of Ro 31-8959. |
